Ankara, Türkiye, 13 May 2025 – MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and Genoks, a leading Turkish clinical laboratory, announced new collaboration to strengthen clinical genetic testing practices in parallel with the advancement of genomic science in Türkiye.

Under this collaboration, MGI will provide advanced DNBSEQ™ sequencing technology to enhance Genoks' offerings in clinical genetic testing, which includes Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Carrier Screening, Hereditary Cancer Screening and more applications in the future.

Combining Genoks’ innovative diagnostic solution and MGI’s competence in sequencing technology, the collaboration is expected to contribute to the effective detection of genetic abnormalities and the improvement of human health in Türkiye.

Stating that thanks to this collaboration, the cooperation between the two companies, which started in 2019, has been further strengthened, Chairman of Genoks, Ozden BOSTAN said, “At Genoks, providing our services quickly and accurately is our top priority. This collaboration with MGI supports our mission that allows more people in Türkiye  to have access to clinical-grade and reliable information about their genetic risk for inherited diseases.”

Dr Christian Zimmermann, VP of Sales at MGI Europe and Africa,  shared his excitement about the partnership and said, “We are proud to strengthen our collaboration with Genoks to improve access to DNBSEQ™ technology in Türkiye. Our partnership reflects our  common goal to  offer more people access to state-of-the-art healthcare, to improve healthcare outcomes and to promote innovation in life sciences.”

About Genoks:

Founded in 2008, Genoks is one of Türkiye's leading organizations in the field of genetics and genomics, successfully representing Türkiye in the international arena. Closely following scientific developments and technological innovations since its establishment, Genoks offers high quality analyses in many fields, especially DNA and RNA sequencing, solid and liquid biopsy-based cancer screening services with its expert staff, experienced scientists and advanced laboratory infrastructure.

Genoks collaborates with approximately 7000 users in more than 15 countries around the world, sharing its knowledge and technology with global stakeholders and thus contributing to science internationally. Having performed more than 200,000 Next Generation Sequencing (NGS) analyses so far, Genoks not only provides diagnostic services, but has also taken an active role in many domestic and international research and development projects.

With its new technology transfers, constantly updated infrastructure and the value it attaches to R&D, Genoks aims to shape not only today's healthcare systems but also those of the future.

For more information, please visit https://www.genoks.com.tr/ and follow our LinkedIn and Instagram accounts.